Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Authors
Keywords
-
Journal
MEDIATORS OF INFLAMMATION
Volume 2013, Issue -, Pages 1-18
Publisher
Hindawi Limited
Online
2013-05-28
DOI
10.1155/2013/549627
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activation of Peroxisome Proliferator-Activated Receptor δ Inhibits Human Macrophage Foam Cell Formation and the Inflammatory Response Induced by Very Low-Density Lipoprotein
- (2012) Lazar A. Bojic et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipid Effects of Peroxisome Proliferator-Activated Receptor-Δ Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol
- (2012) Eric J. Olson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The antiplatelet activity of magnolol is mediated by PPAR-β/γ
- (2012) Ching-Yu Shih et al. BIOCHEMICAL PHARMACOLOGY
- The Role of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer
- (2012) Joo-In Park et al. PPAR Research
- Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
- (2011) Yun-Jung Choi et al. ATHEROSCLEROSIS
- Activation of Peroxisome Proliferator-Activated Receptor- /- (PPAR- /- ) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleukin-6-Stimulated Adipocytes
- (2011) L. Serrano-Marco et al. DIABETES
- Role of Lipid Peroxidation and PPAR-δ in Amplifying Glucose-Stimulated Insulin Secretion
- (2011) Guy Cohen et al. DIABETES
- Inhibitory Effect of α-Lipoic Acid on Platelet Aggregation Is Mediated by PPARs
- (2011) Tz-Chong Chou et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar
- (2011) Stefan Sturm et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
- (2011) Goodarz Danaei et al. LANCET
- Therapeutic applications of compounds in the Magnolia family
- (2011) Young-Jung Lee et al. PHARMACOLOGY & THERAPEUTICS
- Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels
- (2011) A Yessoufou et al. SWISS MEDICAL WEEKLY
- The Nuclear Hormone Receptor PPARγas a Therapeutic Target in Major Diseases
- (2011) Martina Victoria Schmidt et al. TheScientificWorldJOURNAL
- PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells
- (2010) David Álvarez-Guardia et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
- (2010) A. Maida et al. DIABETOLOGIA
- Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
- (2010) Adam J Foley-Comer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
- (2010) Teresa Coll et al. Current Molecular Pharmacology
- Metabolic syndrome and risk of cancer mortality in men
- (2009) Jason R. Jaggers et al. EUROPEAN JOURNAL OF CANCER
- Non-genomic effects of PPARγ ligands: inhibition of GPVI-stimulated platelet activation
- (2009) L. A. MORAES et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Fat and Beyond: The Diverse Biology of PPARγ
- (2008) Peter Tontonoz et al. Annual Review of Biochemistry
- Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor in Cardiac Fibrosis
- (2008) E. Caglayan et al. DIABETES
- Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPARα and PPARδ
- (2008) Pascal J. H. Smeets et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation
- (2007) M.P. Khanolkar et al. ATHEROSCLEROSIS
- Platelet Sarcoplasmic Endoplasmic Reticulum Ca 2+ -ATPase and μ-Calpain Activity Are Altered in Type 2 Diabetes Mellitus and Restored by Rosiglitazone
- (2007) Voahanginirina Randriamboavonjy et al. CIRCULATION
- Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor β/δ (NR1C2) Antagonist
- (2007) Barry G. Shearer et al. MOLECULAR ENDOCRINOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started